Fridays with Dr. Gralow

Editor’s Note: Dr. Julie Gralow is the director of Breast Medical Oncology at SCCA. In celebration of Breast Cancer Awareness Month, we’ve asked Dr. Gralow to answer readers’ questions about breast cancer every Friday during October. If you have a question that you would like to ask Dr. Gralow, please let us know.

This week Dr. Gralow is in Chicago attending the SWOG Fall 2014 Group Meeting. SWOG is a cancer research cooperative group that designs and conducts multidisciplinary clinical trials. So it’s appropriate that she takes on this week’s question: “What are the latest developments in breast cancer research?” In this video, Dr. Gralow talks about four promising areas of research: CDK 4/6 inhibitors, PARP inhibitors, androgen receptors, and immunotherapy.

    Posted in Uncategorized | Leave a comment

    SCCA Providing Mammograms at Remote Area Medical Event

    RAM LogoStarting today, Oct. 23, through Sunday, Oct. 26, SCCA will be providing free mammograms with same-day results at the Seattle/King County Clinic with Remote Area Medical at Seattle Center. SCCA’s MammoVan will be providing cancer-screening services alongside more than 50 health, human service, and civic organizations as part of the four-day, volunteer-driven clinic.

    Humanitarian organization Remote Area Medical organized the clinic, which will provide a full range of free dental, vision, and medical care to underserved and vulnerable populations in our region. The event is open to the public, and no advanced registration is needed. Admission numbers will be distributed starting at 3:30 a.m. each day at Seattle Center’s Key Arena.

    For more information about the clinic, call (206) 684-7200, email skcclinic@seattle.gov, or visit the event website.

      Posted in Cancer Screening | Leave a comment

      SCCA Cancer News Watch

      Here’s a quick summary of notable recent health and cancer news:

      T-Cell Therapy Puts Leukemia Patients in Extended Remission
      Last week the New England Journal of Medicine published the results of a study that showed positive results for patients with advanced lymphoblastic leukemia who were treated using their own T-cells, which had been extracted, genetically modified and then infused back to the patients. Several news outlets reported on the study, including The New York Times and The Verge. The study, which was conducted at Children’s Hospital of Philadelphia and the Hospital of the University of Pennsylvania, is similar to work that’s being done here at SCCA. Earlier this year Patient Power’s Andrew Schorr interviewed Dr. David Maloney about his CAR T-cell study.

      Breast Cancer Awareness Month
      October’s  annual focus on breast cancer has resulted in several nice stories involving SCCA physicians and their patients, including a pair of interviews on King5′s New Day Northwest. The first was with Dr. V.K. Gadi and Ali Spain, who was diagnosed with triple-negative breast cancer a year ago and who recently completed a clinical trial at SCCA under Dr. Gadi’s direction. The second was with Dr. Julie Gralow and Ashley Walker. You can read more about Ashley Walker here. She also documented her cancer journey in this YouTube video.

      In Other Health and Cancer News
      baseball
      How fit are you? The Well reports on a new and improved online fitness calculator developed by The K. G. Jebsen Center of Exercise in Medicine at the Norwegian University of Science and Technology. The Huffington Post looks at what happens to a 10-year-old who donated her hair to cancer patients, the reaction she got from her schoolmates, and then the Internet. And FoxSports reports on a six-year-old cancer patient who will be attending tonight’s World Series game.

       

        Posted in Cancer News Watch | Leave a comment

        Fridays with Dr. Gralow

        Editor’s Note: Dr. Julie Gralow is the director of Breast Medical Oncology at SCCA. In celebration of Breast Cancer Awareness Month, we’ve asked Dr. Gralow to answer readers’ questions about breast cancer every Friday during October. If you have a question that you would like to ask Dr. Gralow, please let us know.

        Today’s question is two-fold: What are the recommendations for screening; and why are there different recommendations for getting a mammogram, in terms of what age you should start and  how often you should get one? In the video below, Dr. Gralow offers a comprehensive and easy-to-understand overview that every woman who has ever wondered about the necessity of mammography should watch.

          Posted in Cancer Screening | Leave a comment

          SCCA Clinical Trial Openings

          Clinical TrialsListed below are clinical trials that have opened at SCCA in the last several weeks. These trials are looking at new treatments for patients with Hodgkin’s lymphoma, relapsed/refractory follicular lymphoma and diffuse large B-cell lymphoma, acute myeloid leukemia, and metastatic prostate cancer.  For more information about these trials, click on the links below. Check out our website to learn about the more than 200 ongoing clinical trials at SCCA. And follow us on Twitter at @SCCA_Trials for information about recently opened trials.

          Brentuximab Vedotin, Ifosfamide, Carboplatin, and Etoposide for Relapsed or Refractory Hodgkin Lymphoma (BV-ICE) (9111)
          A Phase I/II Trial of Brentuximab Vedotin (BV), Ifosfamide (I), Carboplatin (C), and Etoposide (E) for Patients With Relapsed or Refractory Hodgkin Lymphoma (BV-ICE)

          MPDL3280A + Obinutuzumab for Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma (9162)
          A Safety and Pharmacology Study of MPDL3280A Administered With Obinutuzumab in Patients With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma

          Selecting a Favorable KIR Donor in Unrelated HCT for AML (2484)
          KIR Genotyping for Unrelated Donor (URD) Selection Prior to Hematopoietic Cell Transplantation (HCT) for AML: Selecting a Favorable KIR Donor

          DSTP3086S for Metastatic Castration-Resistant Prostate Cancer (20121064)
          A Phase 1, Open-Label Study of the Safety and Pharmacokinetics of Escalating Doses of DSTP30862 in Patients with Metastatic Castration-Resistant Prostate Cancer

            Posted in Clinical Trials | Leave a comment
            • This-One-Thing-260